---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-25-016885"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:48:41.017890+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro director Andrew H. Woo, M.D., Ph.D. passed away on Nov. 14, 2025

## Summary
- Andrew H. Woo served as a director since the company's IPO in June 2021.
- William B. Horne, Chairman, expressed condolences; Woo is succeeded by no replacement yet.
- No other material events reported; financial statements not affected.

## SEC filing metadata
- accession: 0001214659-25-016885
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465925016885/0001214659-25-016885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465925016885/x11172508k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-25-016885
- JSON: https://secwatch.observer/filing/0001214659-25-016885.json
- Plain text: https://secwatch.observer/filing/0001214659-25-016885.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.